Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of “Moderate Buy” by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $81.60.

Several equities research analysts recently commented on HALO shares. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. HC Wainwright restated a “buy” rating and set a $95.00 price target on shares of Halozyme Therapeutics in a report on Tuesday. UBS Group reissued a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the transaction, the director owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 74,102 shares of company stock valued at $5,205,798. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of HALO. Arrowstreet Capital Limited Partnership grew its holdings in Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Halozyme Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after buying an additional 25,731 shares during the period. Norges Bank purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $128,201,000. William Blair Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $124,031,000. Finally, Federated Hermes Inc. grew its stake in shares of Halozyme Therapeutics by 8.5% during the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after acquiring an additional 123,917 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 2.0%

NASDAQ HALO opened at $78.60 on Friday. The firm has a market capitalization of $9.32 billion, a PE ratio of 28.27, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. The business’s 50-day moving average price is $72.40 and its two-hundred day moving average price is $70.35. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics has a 12 month low of $56.05 and a 12 month high of $82.26.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same period in the previous year, the firm earned $1.11 earnings per share. The firm’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts expect that Halozyme Therapeutics will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.